Effect of somatostatin analog on peptide release and tumor growth in the Zollinger-Ellison syndrome.
The clinical presentation of Zollinger-Ellison syndrome (ZES) is the result of gastrin hypersecretion and may be modified by secondary peptide hypersecretion. Treatment is medical (H2-blockers) or surgical (tumor excision and total gastrectomy). H2-blocker escape occurs up to 23 per cent and surgical mortality ranges to 15 per cent. Treatment of advanced disease has limited success. Sandostatin (SMS 201-995) has been shown to decrease basal gastrin and gastric acid secretion in ZES. We hypothesized that SMS would suppress basal and provoked gastrin and secondary peptide secretion in ZES. A patient with refractory, metastatic gastrinoma underwent provocative testing (test meal, calcium infusion, secretion bolus and tolbutamide bolus). Thirteen peptides were drawn at set intervals during these provocative tests. Testing was repeated during SMS therapy (100 micrograms subcutaneously three times per day). Gastrin, pancreatic polypeptide (PP) and glucagon levels were elevated at baseline. SMS suppressed all three peptides (mean 74 per cent) (p less than 0.05). Gastrin, PP and glucagon were provoked by all four tests (means above baseline, 19, 155 and 138 per cent, respectively). Gastrin-releasing peptide, gastric inhibitory peptide and insulin were provoked by calcium infusion (427, 306 and 162 per cent above baseline, respectively). SMS suppressed 14 of 15 of these peaked-provoked peptide levels (mean 72.5 per cent, p less than 0.05). Gastric analysis during calcium infusion showed SMS suppression of hourly gastric secretory volume by 77.5 per cent and of acid production (milliequivalents of acid) by 87.5 per cent. During a 20 month follow-up period, the patient was maintained on SMS, 200 micrograms subcutaneously three times per day. She has remained asymptomatic. Interval peptide profiles at two, eight and 18 months show normal gastrin, PP and glucagon levels. A computed tomographic scan at eight months shows a remarkable regression of primary and metastatic tumor. Regrowth, however, was noted at 19 months. SMS may be useful in ZES by suppressing basal and provoked gastrin and secondary peptide secretion and may occasionally give palliation by yielding temporary tumor registration.
Mozell
E
E
Department of Surgery, Oregon Health Sciences University, Portland.
Woltering
E A
EA
O'Dorisio
T M
TM
Fletcher
W S
WS
Sinclair
A J
AJ
Hill
D
D
D000368:Aged; D002118:Calcium; D005260:Female; D005502:Food; D005755:Gastrins / Q000097:blood / Q000378:metabolism*; D005768:Gastrointestinal Hormones / Q000378:metabolism; D005934:Glucagon / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D015282:Octreotide / Q000627:therapeutic use*; D010191:Pancreatic Polypeptide / Q000378:metabolism; D012633:Secretin; D014044:Tolbutamide; D015043:Zollinger-Ellison Syndrome / Q000097:blood / Q000188:drug therapy* / Q000473:pathology
D005755:Gastrins; D005768:Gastrointestinal Hormones; D007328:Insulin; D012633:Secretin; D010191:Pancreatic Polypeptide; D005934:Glucagon; D014044:Tolbutamide; D015282:Octreotide; D002118:Calcium